Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data.

ABSTRACT:

Objective

To assess the risk of hypertension in patients with migraine who received erenumab in clinical trials and in the postmarketing setting.

Background

Erenumab is a monoclonal antibody for migraine prevention that targets the calcitonin gene-related peptide (CGRP) receptor. Hypertension is a theoretical risk for inhibitors of the CGRP pathway. Although no evidence of an association between erenumab treatment and hypertension was observed during the clinical development program, adverse events (AEs) of hypertension have been identified in the postmarketing setting.

Methods

Safety data from four phase 2 and phase 3 clinical trials were used to perform a pooled analysis of hypertension AEs in patients with migraine receiving erenumab. Postmarketing AEs of hypertens

SUBMITTER: Dodick DW 

PROVIDER: S-EPMC9293040 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature